Acciones Mateon Therapeutics Inc Nasdaq
Acciones
US57667K1097
Biotecnología e investigación médica
Ventas 2022 | - | Ventas 2023 | 0,07 0,06 | Capitalización | 15,27 M 14,02 M |
---|---|---|---|---|---|
Resultado Neto 2022 | 5 M 4,59 M | Resultado Neto 2023 | -7 M -6,43 M | VE / Ventas 2022 | - |
Deuda neta 2022 | 11,02 M 10,12 M | Deuda neta 2023 | 12,4 M 11,39 M | VE / Ventas 2023 | 395.316.686 x |
P/E ratio 2022 |
4,5
x | P/E ratio 2023 |
-1,91
x | Empleados | - |
Rendimiento 2022 * |
-
| Rendimiento 2023 |
-
| Flotante | 45,17 % |
Directores | Puesto | Edad | Desde |
---|---|---|---|
Vuong Trieu
CEO | Chief Executive Officer | 59 | 22/04/19 |
Director of Finance/CFO | 57 | 01/07/19 | |
Seymour H. Fein
CTO | Chief Tech/Sci/R&D Officer | 75 | 06/01/20 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Steven King
BRD | Director/Board Member | 59 | 11/05/20 |
Anthony Maida
CTO | Chief Tech/Sci/R&D Officer | 59 | 11/05/20 |
Vuong Trieu
CEO | Chief Executive Officer | 59 | 22/04/19 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+18,72 % | 125 mil M | |
+14,53 % | 109 mil M | |
-2,88 % | 24,74 mil M | |
+2,18 % | 22,67 mil M | |
-10,09 % | 18,14 mil M | |
-41,04 % | 16,67 mil M | |
-11,83 % | 16,64 mil M | |
+1,46 % | 13,45 mil M | |
+24,22 % | 11,32 mil M |